Stock NTBL NOTABLE LABS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-04-11 pm EDT 		5-day change 1st Jan Change
1.16 USD -4.13% Intraday chart for Notable Labs, Ltd. -22.15% -38.62%
Apr. 15 Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating MT
Apr. 15 Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating MT

Evolution of the average Target Price on Notable Labs, Ltd.

Price target over the last 5 years

History of analyst recommendation changes

a69bee30adcc48415.8F-4mNNBacJFvKiyg1jqOkXzJY9JBbWm76jsB30AyC8.uXLU3J8KLqMLyZji0h6ZTxSsCOktfeKVhN3UQxZGkl2hHfe1mAkbkCfxxw~ea4354c542bdf5f5b5fe7e5798fab7a2

Analyst Recommendations on Notable Labs, Ltd.

Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating MT
Chardan Research Downgrades Vascular Biogenics to Neutral From Buy After OVAL Trial Fails to Meeting Enpoints MT
Oppenheimer Downgrades Vascular Biogenics to Perform From Outperform, Removes $5.50 Price Target MT
HC Wainwright Downgrades Vascular Biogenics to Neutral From Buy MT
Chardan Capital Initiates Vascular Biogenics at Buy with $5 Price Target MT
VASCULAR BIOGENICS : Chardan Suspends Coverage on Vascular Biogenics at Buy Rating With $5 Price Target MT
VASCULAR BIOGENICS : Roth Capital Adjusts Vascular Biogenics PT to $7 From $5, Maintains Buy Rating MT
VASCULAR BIOGENICS : Guggenheim Starts Vascular Biogenics at Buy With $7 Price Target MT
VASCULAR BIOGENICS : HC Wainwright Adjusts Vascular Biogenics' Price Target to $4 from $3, Keeps Buy Rating MT
VASCULAR BIOGENICS : Oppenheimer Adjusts Vascular Biogenics PT to $5 From $2.50, Maintains Outperform Rating MT
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer At the ASCO 20 Annual Meeting, Showing 58% or Higher Objective Response Rate CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.18 USD
Average target price
8 USD
Spread / Average Target
+578.08%
High Price Target
9 USD
Spread / Highest target
+662.84%
Low Price Target
7 USD
Spread / Lowest Target
+493.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Notable Labs, Ltd.

Chardan Research
JMP Securities
HC Wainwright
Oppenheimer
Chardan
Roth Capital Partners
Guggenheim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NTBL Stock
  4. Consensus Notable Labs, Ltd.